Cancer Institute– A national cancer institute
designated cancer center

Susan Knox

Back to Profile

Publication Details

  • The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts.

    Wilder RB, McGann JK, Sutherland WR, Waller EK, Minchinton AI, Goris ML, Knox SJ. Int J Radiat Oncol Biol Phys. 1994; 28 (1): 119-26

    To determine if either the hypoxic cell radiosensitizer etanidazole (SR 2508) or the hypoxic cytotoxin SR 4233 could improve the effectiveness of radioimmunotherapy.

    PubMedID: 8270432

Stanford Medicine Resources:

Footer Links: